Search results for "Original Reports"

showing 5 items of 15 documents

Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA Studies.

2015

Purpose Recent literature reports a potential association between high vitamin D and improved lymphoma prognosis. We evaluated the impact of pretreatment vitamin D on follicular lymphoma (FL) outcome. Patients and Methods SWOG participants were previously untreated patients with FL enrolled onto SWOG clinical trials (S9800, S9911, or S0016) involving CHOP chemotherapy plus an anti-CD20 antibody (rituximab or iodine-131 tositumomab) between 1998 and 2008. Participants included in our second independent cohort were also previously untreated patients with FL enrolled onto the Lymphoma Study Association (LYSA) PRIMA trial of rituximab plus chemotherapy (randomly assigned to rituximab maintenanc…

MaleCancer Researchmedicine.medical_specialtyTime FactorsFollicular lymphomaKaplan-Meier EstimateCHOPGastroenterologyTositumomabDisease-Free SurvivalRisk FactorsTandem Mass SpectrometryInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineVitamin D and neurologyHumansProspective StudiesVitamin DProspective cohort studyCyclophosphamideLymphoma FollicularProportional Hazards Modelsbusiness.industryHazard ratioAntibodies MonoclonalORIGINAL REPORTSMiddle Agedmedicine.diseaseVitamin D DeficiencySurgeryTreatment OutcomeOncologyDoxorubicinVincristineCohortDisease ProgressionPrednisoneRituximabFemalebusinessRituximabBiomarkersmedicine.drugChromatography LiquidJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcome…

2016

Purpose The Suppression of Ovarian Function trial showed improved disease control for tamoxifen plus ovarian function suppression (OFS) compared with tamoxifen alone for the cohort of premenopausal patients who received prior chemotherapy. We present the patient-reported outcomes. Patients and Methods The quality-of-life (QoL) analysis includes 1,722 of 2,045 premenopausal patients with hormone receptor–positive breast cancer randomly assigned to receive adjuvant treatment with 5 years of tamoxifen plus OFS or tamoxifen alone. Chemotherapy use before enrollment was optional. Patients completed a QoL form consisting of global and symptom indicators at baseline, every 6 months for 24 months, …

OncologyAdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOvaryBreast Neoplasmslaw.invention03 medical and health sciences0302 clinical medicineBreast cancerRandomized controlled trialQuality of lifelawInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumans030212 general & internal medicineChemotherapyTriptorelin Pamoatebusiness.industryOvaryRepeated measures designORIGINAL REPORTSmedicine.diseaseAndrostadienesTamoxifenmedicine.anatomical_structureOncologyPremenopauseChemotherapy Adjuvant030220 oncology & carcinogenesisLymphatic MetastasisCohortQuality of LifeFemaleSelf ReportbusinessTamoxifenmedicine.drug
researchProduct

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Gr…

2020

Purpose: For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome. Patients and methods: Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIO…

OncologyCancer Researchmedicine.medical_specialtyGenomicsNeuroblastomaCogInternal medicineNeuroblastomaHumansMedicineProgression-free survivalSurvival rateNeoplasm StagingChromosome AberrationsClinical Trials as TopicN-Myc Proto-Oncogene ProteinValidation groupbusiness.industryChromosomes Human Pair 11Age FactorsGene AmplificationInfantORIGINAL REPORTSGenomicsPrognosismedicine.diseaseDiploidyProgression-Free SurvivalDoenças GenéticasSurvival RateOncologyPediatric OncologyChromosomes Human Pair 1Mycn amplificationNeoplasm stagingbusinessJournal of Clinical Oncology
researchProduct

Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Pr…

2021

PURPOSE A dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) regimen has been shown to deliver excellent survival for adults with primary mediastinal large B-cell lymphoma (PMLBL) without the use of radiotherapy. No international prospective evaluation of this regimen has previously been reported in children and adolescents. PATIENTS AND METHODS We conducted an international single-arm phase II trial involving patients younger than age 18 years with PMLBL who were to receive six courses of DA-EPOCH-R. The primary end point was event-free survival (EFS). Overall survival and toxicity were also assessed. This trial was regist…

OncologyCancer Researchmedicine.medical_specialtyVincristineCyclophosphamidebusiness.industryORIGINAL REPORTSmedicine.diseaseRegimenOncologyPrednisoneInternal medicinemedicineRituximabDoxorubicinPrimary mediastinal B-cell lymphomabusinessEtoposidemedicine.drugJournal of Clinical Oncology
researchProduct

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

2017

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malatti…

OncologyMaleCancer ResearchTime FactorsAngiogenesis InhibitorsKaplan-Meier Estimatelaw.invention0302 clinical medicineAutologous stem-cell transplantationMaintenance therapyRandomized controlled triallawRisk FactorsClinical endpointMedicine10. No inequalityLenalidomideAdjuvantMultiple myelomaRandomized Controlled Trials as TopicHematopoietic Stem Cell TransplantationMESH: Angiogenesis Inhibitors/administration & dosageORIGINAL REPORTSMiddle Aged3. Good healthThalidomideAdult; Aged; Angiogenesis Inhibitors; Chemotherapy Adjuvant; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Risk Factors; Thalidomide; Time Factors; Transplantation Autologous; Treatment Outcome; Young Adult; Stem Cell TransplantationTreatment OutcomeOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisDisease ProgressionMESH: Multiple Myeloma/therapyFemaleMultiple MyelomaAutologousmedicine.drugAdultmedicine.medical_specialtyMESH: Thalidomide/analogs & derivatives[SDV.CAN]Life Sciences [q-bio]/CancerTransplantation AutologousDisease-Free SurvivalDrug Administration ScheduleMaintenance Chemotherapy03 medical and health sciencesYoung AdultInternal medicineChemotherapyHumansLenalidomideAgedTransplantationbusiness.industrymedicine.diseaseThalidomideTransplantationbusiness030215 immunologyStem Cell Transplantation
researchProduct